GCGR and type 2 diabetes mellitus: Despite promising results in preclinical models of T2D, as well as efficacy observed in early clinical studies, the adverse event profile seen in humans, particularly elevated liver fat deposition and liver enzymes, has limited the clinical utility of glucagon receptor antagonists (152).